Literature DB >> 24441289

Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients.

G Visani1, F Ferrara2, F Di Raimondo3, F Loscocco1, G Sparaventi1, S Paolini4, F Fuligni4, A Gazzola4, M Rossi4, M A Laginestra4, M R Caraci3, C Riccardi2, M Rocchi5, A Visani4, S A Pileri4, P P Piccaluga4, A Isidori1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24441289     DOI: 10.1038/leu.2014.31

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype.

Authors:  E Scherman; S Malak; C Perot; N C Gorin; M T Rubio; F Isnard
Journal:  Leukemia       Date:  2011-10-14       Impact factor: 11.528

2.  A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML.

Authors:  G Ramsingh; P Westervelt; A F Cashen; G L Uy; K Stockerl-Goldstein; C N Abboud; N Bernabe; R Monahan; J F DiPersio; R Vij
Journal:  Leukemia       Date:  2012-07-25       Impact factor: 11.528

3.  A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.

Authors:  Todd A Fehniger; Geoffrey L Uy; Kathryn Trinkaus; Alissa D Nelson; Jeffery Demland; Camille N Abboud; Amanda F Cashen; Keith E Stockerl-Goldstein; Peter Westervelt; John F DiPersio; Ravi Vij
Journal:  Blood       Date:  2010-11-04       Impact factor: 22.113

Review 4.  Gene expression profiling in MDS and AML: potential and future avenues.

Authors:  K Theilgaard-Mönch; J Boultwood; S Ferrari; K Giannopoulos; J M Hernandez-Rivas; A Kohlmann; M Morgan; B Porse; E Tagliafico; C M Zwaan; J Wainscoat; M M Van den Heuvel-Eibrink; K Mills; L Bullinger
Journal:  Leukemia       Date:  2011-03-29       Impact factor: 11.528

Review 5.  How to manage high-risk acute myeloid leukemia.

Authors:  E H Estey
Journal:  Leukemia       Date:  2011-11-25       Impact factor: 11.528

6.  Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study.

Authors:  Pier Paolo Piccaluga; Fabio Fuligni; Antonio De Leo; Clara Bertuzzi; Maura Rossi; Francesco Bacci; Elena Sabattini; Claudio Agostinelli; Anna Gazzola; Maria Antonella Laginestra; Claudia Mannu; Maria Rosaria Sapienza; Sylvia Hartmann; Martin L Hansmann; Roberto Piva; Javeed Iqbal; John C Chan; Denis Weisenburger; Julie M Vose; Monica Bellei; Massimo Federico; Giorgio Inghirami; Pier Luigi Zinzani; Stefano A Pileri
Journal:  J Clin Oncol       Date:  2013-07-15       Impact factor: 44.544

7.  Dose escalation of lenalidomide in relapsed or refractory acute leukemias.

Authors:  William Blum; Rebecca B Klisovic; Heiko Becker; Xiaoxia Yang; Darlene M Rozewski; Mitch A Phelps; Ramiro Garzon; Alison Walker; Jason C Chandler; Susan P Whitman; John Curfman; Shujun Liu; Larry Schaaf; Jon Mickle; Cheryl Kefauver; Steven M Devine; Michael R Grever; Guido Marcucci; John C Byrd
Journal:  J Clin Oncol       Date:  2010-10-18       Impact factor: 44.544

Review 8.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors:  Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

9.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

Authors:  Timothy J Ley; Christopher Miller; Li Ding; Benjamin J Raphael; Andrew J Mungall; A Gordon Robertson; Katherine Hoadley; Timothy J Triche; Peter W Laird; Jack D Baty; Lucinda L Fulton; Robert Fulton; Sharon E Heath; Joelle Kalicki-Veizer; Cyriac Kandoth; Jeffery M Klco; Daniel C Koboldt; Krishna-Latha Kanchi; Shashikant Kulkarni; Tamara L Lamprecht; David E Larson; Ling Lin; Charles Lu; Michael D McLellan; Joshua F McMichael; Jacqueline Payton; Heather Schmidt; David H Spencer; Michael H Tomasson; John W Wallis; Lukas D Wartman; Mark A Watson; John Welch; Michael C Wendl; Adrian Ally; Miruna Balasundaram; Inanc Birol; Yaron Butterfield; Readman Chiu; Andy Chu; Eric Chuah; Hye-Jung Chun; Richard Corbett; Noreen Dhalla; Ranabir Guin; An He; Carrie Hirst; Martin Hirst; Robert A Holt; Steven Jones; Aly Karsan; Darlene Lee; Haiyan I Li; Marco A Marra; Michael Mayo; Richard A Moore; Karen Mungall; Jeremy Parker; Erin Pleasance; Patrick Plettner; Jacquie Schein; Dominik Stoll; Lucas Swanson; Angela Tam; Nina Thiessen; Richard Varhol; Natasja Wye; Yongjun Zhao; Stacey Gabriel; Gad Getz; Carrie Sougnez; Lihua Zou; Mark D M Leiserson; Fabio Vandin; Hsin-Ta Wu; Frederick Applebaum; Stephen B Baylin; Rehan Akbani; Bradley M Broom; Ken Chen; Thomas C Motter; Khanh Nguyen; John N Weinstein; Nianziang Zhang; Martin L Ferguson; Christopher Adams; Aaron Black; Jay Bowen; Julie Gastier-Foster; Thomas Grossman; Tara Lichtenberg; Lisa Wise; Tanja Davidsen; John A Demchok; Kenna R Mills Shaw; Margi Sheth; Heidi J Sofia; Liming Yang; James R Downing; Greg Eley
Journal:  N Engl J Med       Date:  2013-05-01       Impact factor: 91.245

Review 10.  Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?

Authors:  U Platzbecker; U Germing
Journal:  Leukemia       Date:  2013-05-06       Impact factor: 11.528

View more
  3 in total

1.  Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML.

Authors:  Giuseppe Visani; Federica Loscocco; Mike Dennis; Eliana Zuffa; Anna Candoni; Alberto Sensi; Barbara Giannini; Gerardo Musuraca; Anna Maria Mianulli; Marino Clavio; Marco Rocchi; Davide Gibellini; Mohsen Navari; Amanda Gilkes; Pier Paolo Piccaluga; Alessandro Isidori
Journal:  Blood Adv       Date:  2020-10-27

2.  Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis.

Authors:  Chun-Hong Xie; Min Wei; Fei-Yan Yang; Fu-Zhen Wu; Lei Chen; Jian-Kun Wang; Qin Liu; Jin-Xiong Huang
Journal:  Cancer Manag Res       Date:  2018-09-18       Impact factor: 3.989

3.  Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?

Authors:  Shannon R McCurdy; Selina M Luger
Journal:  Haematologica       Date:  2021-10-01       Impact factor: 9.941

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.